Ceragenix Pharmaceuticals, Inc. Form 8-K Current Report (June 28, 2005)

Contract Categories: Business Operations › MOUs
Summary

Ceragenix Pharmaceuticals, Inc. filed this Form 8-K to announce that Dr. Paul B. Savage presented research data on the company's Cationic Steroid Antibiotic technology at a national infectious disease conference. The report includes a press release dated June 28, 2005, and is signed by the company's CEO, Steven S. Porter. This filing serves to inform investors and the public of significant company developments as required by SEC regulations.

Read More Arrow
EX-1.0 2 pr-628.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 28, 2005

CERAGENIX PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)

       Delaware       

       000-50470       

    84-1561463    

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)

1444 Wazee Street, Suite 210, Denver, Colorado 80202
(Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code:   (720) 946-6440

___________________________________________________
(Former name or former address, if changed since last report)

ITEM 7.01

REGULATION FD DISCLOSURE

          On June 28, 2005, the Company issued a press release announcing that Dr. Paul B. Savage (Professor of Chemistry and Biochemistry at Brigham Young University) presented data in two poster presentations from in-vitro studies on Ceragenix's Cationic Steroid Antibiotic technology at the National Foundation for Infectious Disease's annual meeting on Antimicrobial Resistance on June 27th in Bethesda, Maryland (www.nfid.org). A copy of the press release is filed herewith.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS


(c)


Exhibits

  
       
 

Item

Title
 

1.0

Press Release dated June 28, 2005

 

SIGNATURES

       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

   

Ceragenix Pharmaceuticals, Inc.
(Registrant)
       

Dated: June 30, 2005 

/s/ Steven S. Porter                                    
Steven S. Porter, Chief Executive Officer